Product Description
AL-58805 is being developed by Zhejiang University for the treatment of cancer. (Sourced from: )
Mechanisms of Action: mTOR Inhibitor, PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07179081 |
AL58805-CN-001B | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-01-26 |
12% |
2025-09-18 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|